Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Dana-Farber’s Philip Kranzusch receives prestigious New Innovator Award from the National Institutes of Health

Philip Kranzusch, PhD of Dana-Farber Cancer Institute has received the New Innovator Award from the National Institutes of Health’s High-Risk, High-Reward Research program. The prestigious award supports exceptionally creative early career investigators pursuing highly innovative research with the potential for broad impact in biomedical, behavioral, or social sciences.

Kranzusch, a Principal Investigator in the Cancer Immunology and Virology Department at Dana-Farber is recognized among 106 other highly distinguished innovative scientists and will receive funding $1,500,000 over five years to further his impact on and address challenges in relation to biomedical science.

Kranzusch’s lab investigates how cells respond to pathogens and how scientists might use those response pathways to develop new therapies for cancer and autoimmune diseases. In one branch of his research, he aims to uncover the detailed workings of a cell signaling pathway called cGAS-STING, which helps cells recognize abnormal DNA and has piqued some researchers' interest as a potential avenue for training the immune system to fight cancer.

“The science put forward by this cohort is exceptionally novel and creative and is sure to push at the boundaries of what is known,” said NIH Director Francis S. Collins, M.D., Ph.D. “These visionary investigators come from a wide breadth of career stages.

The High-Risk, High-Reward Research program is aimed at supporting compelling, high-risk research proposals that may struggle in the traditional peer review process despite their transformative potential. The program consists of four awards: The NIH Director’s Pioneer Award, New Innovator Award, Transformative Research Award and Early Independence Award.

Posted on October 05, 2021

  • Philip Kranzusch, PhD

Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.

Philip Kranzusch, PhD